OVERVIEW OF THE PHARMACEUTICAL MARKET IN SERBIA
While the market is small in terms of absolute numbers, relative per capita spending on medicines is expected to improve over the long term. As the country continues its economic convergence with developed Europe, drug consumption is also expected to rise. However, financial inefficiencies within the health insurance system mean that the National Health Insurance Institution ( RZZO ) is unable to always meet its obligations on time, leaving patients to pay for formerly reimbursed medicines or hospitals having to cover the difference .
Headline Expenditure Projections
- Pharmaceuticals: RSD75.70bn (US$1.03bn) in 2011 to RSD81.44bn (US$0.92bn) in 2012; +7.6% in local currency terms and -11.0% in US dollar terms.
- Healthcare: RSD347.71bn (US$4.74bn) in 2011 to RSD367.32bn (US$4.14bn) in 2012; +5.6% in local currency terms and -12.6% in US dollar terms.
Inquire Before buying the Report @ Serbia Pharmaceutical Market
Table of Contents
Serbia Pharmaceuticals And Healthcare Industry SWOT
Serbia Political SWOT Analysis
Serbia Economic SWOT Analysis
Serbia Business Environment SWOT Analysis
Pharmaceutical Risk/Reward Ratings
Table: Emerging Europe Regional Pharma Risk/Reward Ratings for Q21310
Table: The Number of Products on the Drugs List
Corruption In The Healthcare Sector
Intellectual Property Environment
Market Research Reports.biz is the most comprehensive collection of market research reports. Marketresearchreports.biz services are especially designed to save time and money of our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
90 Sate Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: +1-866-997-4948
Browse Market Research Blog